We believe there is a significant demand for improvement of tumor profiling through reduced usage of precious tissue specimens, platform consolidation, and optimization of testing efficiency. Lung cancer is an area in which we are initially focused, and we plan to develop a single solution that provides testing for:
- Fusions and rearrangements (including ALK)
- Hotspot mutations (including EGFR)
- Histology classification
Our broader approach to tumor profiling includes solutions for breast, lung, prostate, colon and thyroid cancers and may include testing for microRNA expression as well as gene copy number variations.